Samsung Biologics
Samsung Biologics is one of the most important biologics CDMO providers globally and a defining player in large-scale mammalian cell culture manufacturing. The company has built a highly standardized, large-capacity manufacturing platform in South Korea, serving major pharmaceutical and biotechnology clients across biologics development and commercial supply.
- Highest 2026 tier: Tier I
- Biomanufacturing & CDMO Providers
- 1 ranking category
Overview
Samsung Biologics is one of the most important biologics CDMO providers globally and a defining player in large-scale mammalian cell culture manufacturing. The company has built a highly standardized, large-capacity manufacturing platform in South Korea, serving major pharmaceutical and biotechnology clients across biologics development and commercial supply.
Samsung Biologics’ strength lies in scale, execution, and standardization. Its manufacturing campus in Songdo has become one of the largest biologics manufacturing platforms in the world, with a business model centered on operational efficiency, quality systems, and large-volume production.
Samsung Biologics is included in 1 2026 ranking category. Its highest classification is Tier I. Ranking recognition is category-specific editorial evidence rather than a substitute for independent diligence.
Firm facts
| Public identity | Samsung Biologics |
| Founded | 2011 |
| Institution type | Biomanufacturing & CDMO Providers institution |
| Headquarters | Incheon, South Korea |
| Primary focus | Biomanufacturing & CDMO Providers |
| Highest 2026 ranking tier | Tier I |
Principal activities
Samsung Biologics’ strength lies in scale, execution, and standardization. Its manufacturing campus in Songdo has become one of the largest biologics manufacturing platforms in the world, with a business model centered on operational efficiency, quality systems, and large-volume production.
Core capability
Biomanufacturing & CDMO Providers
Client relevance
Category-specific capability, institutional credibility and the ability to support demanding professional, commercial or patient needs.
Execution and verification
Current service scope, leadership, geographic coverage, legal entities and regulated activities should be confirmed directly.
Sector and mandate coverage
Primary category
Biomanufacturing & CDMO Providers
Institutional context
Coverage reflects the institution’s role in the ranking categories listed below. Precise services, products, jurisdictions, clinical scope and client eligibility should be verified for each use case.
Market position
Samsung Biologics’ biologics manufacturing capacity, global sponsor relationships, quality systems, and execution-oriented operating model support its position among the leading global CDMO providers.
Samsung Biologics is assessed through public institutional information and Ranking News editorial research. Its strongest 2026 result is Tier I.
Competitive context
The relevant peer set varies by category, geography, client segment and mandate. Samsung Biologics should be compared on current category-specific capability, senior involvement, evidence of comparable work, operating resilience and any applicable regulatory or clinical permissions.
Comparable institutions are shown for navigation and market context. Inclusion does not imply identical scale, ownership, geographic coverage, service model or regulatory status.
Leadership and governance
Leadership, ownership, governance and senior-team responsibilities may change. Current information should be verified through authoritative institutional sources.
Corporate and public information
The public-facing organization is identified here as Samsung Biologics. Contracting entities, regulated affiliates, clinical operations, offices and legal permissions may differ by service and jurisdiction.
Corporate and disclosure information
| Organization | Samsung Biologics |
| Headquarters | Incheon, South Korea |
| Verification note | Confirm legal entity, licenses, offices and engagement terms directly before appointment or use. |
Rankings and recognition
Ranking inclusion and tier classification are editorial determinations. They should be read as category-specific assessments rather than universal league-table positions. The existence or maintenance of this Wiki profile does not influence ranking eligibility, tier or position.
Related Economy analysis
Selected reporting and market analysis from The Economy provides context for the institution’s operating environment:
- Healthcare Rankings and the New Economics of Expertise
- Healthcare Market Structure Is Opening a New Lane for Specialist Providers
- Healthcare Rankings and the New Geography of Distributed Care
Related institutions and subjects
Sources and data transparency
Official institutional information, where available, is used for current public identity and capabilities. Ranking pages document 2026 category and tier status. Economy articles provide market context rather than institution-specific endorsement.
- Healthcare Ranking — Top 30 Biomanufacturing & CDMO Providers 2026 — 2026 inclusion and tier classification.
- The Economy — Healthcare Rankings and the New Economics of Expertise — market context.
- The Economy — Healthcare Market Structure Is Opening a New Lane for Specialist Providers — market context.
- The Economy — Healthcare Rankings and the New Geography of Distributed Care — market context.
